Spermosens provides update on clinical progress, partner discussions and financing
Non-regulatorySpermosens AB (“Spermosens” or the “Company”) provides an update on its ongoing clinical study, commercial discussions and financing.
Read morePressreleases
Spermosens reports positive second interim results from clinical study
RegulatorySpermosens AB (“Spermosens” or the “Company”) announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company´s patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first interim analysis released in December 2024. Specifically, the results continue to demonstrate correlation between the JUNO binding and fertility outcomes.
Read moreSpermosens appoints Dr. Jaime Castillo-León as chief technology officer to drive innovation and technology development
Non-regulatorySpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team’s technology expertise is a key step in executing the Company’s recently announced plan to achieve positive cash flow from the second half of 2026.
Read moreSpermosens AB announces strategic collaboration with Scalania AG to accelerate development and market readiness
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) announces a strategic collaboration with Scalania AG (“Scalania”), part of the UNITY Innovation Alliance, to accelerate the development and market readiness of its unique JUNO-Checked technology. Following the previous announcement on March 4th, 2025, the Company has now entered into a strategic collaboration agreement with Scalania, effective from April 2025.
Read moreSpermosens publishes peer-reviewed article on JUNO-Checked technology
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that a peer-reviewed article, “JUNO-Checked – A Live Cell Electrochemical Biosensor for Sperm Function Diagnostics,” has been published in the prestigious journal Sensors & Diagnostics by the Royal Society of Chemistry. This gold open-access journal is renowned for showcasing cutting-edge research on sensing technologies and diagnostic systems, with a particular focus on novel materials, innovative detection methods and advancements that enable in situ or real-world testing.
Read moreSpermosens presents plan to achieve positive cash flow following recent strategic investment
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens aims to establish licensing agreements with leading players in the assisted reproductive technology (ART) market in the second half of 2026, positioning the company to achieve positive cash flow.
Read moreSpermosens announces outcome of TO3 warrants
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024.
Read moreSpermosens secures SEK 10.8 million strategic investment through directed issue, fulfilling capital need until cash positive
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income from license agreements with established partners in the global Assisted Reproductive Technology (ART) market.
Read moreSpermosens announces last day of trading for warrants of series TO3
RegulatorySpermosens AB (“Spermosens” or “the Company”) announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025.
Read moreSpermosens AB announces shareholding changes following latest directed issue
RegulatorySpermosens AB (publ) announces changes in its shareholding structure following the latest directed issue. An update of the shareholder structure was made prior to the extraordinary general meeting held on 17 February 2025.
Read moreKommuniké från extra bolagsstämma i Spermosens AB (publ) den 17 februari 2025
RegulatorySpermosens AB (publ) höll den 17 februari 2025 extra bolagsstämma varvid i huvudsak följande beslut fattades. Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade, i enlighet med styrelsens förslag, att bemyndiga styrelsen att ändra bolagets bolagsordning genom att anta nya gränser för aktiekapitalet respektive antalet aktier i syfte att möjliggöra emission av aktier och teckningsoptioner. Styrelsen är därmed bemyndigad att ändra bolagets bolagsordning till det av Alternativ A–B som behövs för att möjliggöra emissionerna.
Read moreAnnouncement from the Extraordinary General Meeting of Spermosens AB (publ) on 17 February 2025
RegulatorySpermosens AB (publ) held an Extraordinary General Meeting on 17 February 2025, during which the following key resolutions were adopted. Resolution to Amend the Articles of Association The Extraordinary General Meeting resolved, in accordance with the Board’s proposal, to authorize the Board to amend the company’s Articles of Association by adopting new limits for share capital and the number of shares to enable the issuance of shares and warrants. The Board is thus authorized to amend the Articles of Association to either of the following alternatives as required to facilitate the issuances:
Read more
Spermosens Logotype
